HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

About this item

Title

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Content partner

Directory of Open Access Journals

Collection

Directory of Open Access Journals

Description

Abstract Background HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with anthracyclines. The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy. Methods In a series of 352 breast carcinoma tissues from patients that had been ...

Read more

Format

Research paper

Date created

2012-01-01

Creator

Fountzilas George / Valavanis Christos / Kotoula Vassiliki / Eleftheraki Anastasia G / Kalogeras Konstantine T / Tzaida Olympia / Batistatou Anna / Kronenwett Ralf / Wirtz Ralph M / Bobos Mattheos / Timotheadou Eleni / Soupos Nikolaos / Pentheroudakis George / Gogas Helen / Vlachodimitropoulos Dimitrios / Polychronidou Genovefa / Aravantinos Gerasimos / Koutras Angelos / Christodoulou Christos / Pectasides Dimitrios / Arapantoni Petroula

Contributing partner

Journal of Translational Medicine

URL

http://www.translational-medicine.com/content/10/1/10

Related subjects

HER2 / TOP2A / gene amplification / CISH / mRNA expression / early breast cancer / randomized study / anthracyclines / taxanes / Medicine

What is the copyright status of this item?

Share, Modify, Use commercially

See below for specifics about how you may use this item.

More Information

Directory of Open Access Journals has this to say about the rights status of this item:

CC BY (All metadata for this Directory of Open Access Journals record is available under the Creative Commons Attribution-ShareAlike License (CC BY-SA).)

You can learn more about the rights status of this item at: http://www.biomedcentral.com/getpublished/copyright-and-license

What can I do with this item?

You must always check with Directory of Open Access Journals to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

Share it

This item is suitable for copying and sharing with others, without further permission.

Modify it

This item is suitable for modifying, remixing and building upon, without further permission.

Use it commercially

This item is suitable for commercial use, without further permission.